AQR Capital Management
PDLI

AQR Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

AQR Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-262,907
Closed -$828K – 2323
2020
Q3 		$828K Sell
262,907
-690,958
-72% -$2.21M ﹤0.01% 1517
2020
Q2 		$2.78M Sell
953,865
-425,522
-31% -$1.35M ﹤0.01% 1018
2020
Q1 		$3.89M Sell
1,379,387
-855,089
-38% -$2.76M 0.01% 864
2019
Q4 		$7.25M Buy
2,234,476
+496,599
+29% +$1.44M 0.01% 853
2019
Q3 		$3.75M Sell
1,737,877
-1,836
-0.1% -$4.91K ﹤0.01% 1062
2019
Q2 		$5.46M Sell
1,739,713
-637,341
-27% -$2.07M 0.01% 951
2019
Q1 		$8.84M Buy
2,377,054
+116,205
+5% +$392K 0.01% 818
2018
Q4 		$6.56M Sell
2,260,849
-632,800
-22% -$1.74M 0.01% 861
2018
Q3 		$7.61M Sell
2,893,649
-1,397,794
-33% -$3.43M 0.01% 865
2018
Q2 		$10M Sell
4,291,443
-535,662
-11% -$1.5M 0.01% 784
2018
Q1 		$14.2M Sell
4,827,105
-531,220
-10% -$1.45M 0.02% 678
2017
Q4 		$14.7M Buy
5,358,325
+554,020
+12% +$1.7M 0.02% 680
2017
Q3 		$16.3M Buy
4,804,305
+443,319
+10% +$1.23M 0.02% 638
2017
Q2 		$10.8M Sell
4,360,986
-185,515
-4% -$427K 0.01% 757
2017
Q1 		$10.3M Buy
4,546,501
+820,481
+22% +$1.81M 0.01% 758
2016
Q4 		$7.9M Buy
3,726,020
+975,233
+35% +$2.72M 0.01% 840
2016
Q3 		$9.21M Buy
2,750,787
+501,874
+22% +$1.59M 0.01% 790
2016
Q2 		$7.06M Buy
2,248,913
+200,044
+10% +$667K 0.01% 808
2016
Q1 		$6.82M Sell
2,048,869
-3,718
-0.2% -$11.6K 0.01% 791
2015
Q4 		$7.27M Buy
2,052,587
+1,735,879
+548% +$7.27M 0.01% 799
2015
Q3 		$1.59M Buy
316,708
+181,555
+134% +$1.04M ﹤0.01% 1235
2015
Q2 		$869K Buy
135,153
+108,489
+407% +$727K ﹤0.01% 1566
2015
Q1 		$188K Sell
26,664
-23,670
-47% -$171K ﹤0.01% 2023
2014
Q4 		$388K Sell
50,334
-177,375
-78% -$1.4M ﹤0.01% 2078
2014
Q3 		$1.7M Sell
227,709
-1,216,751
-84% -$11.3M ﹤0.01% 1351
2014
Q2 		$14M Sell
1,444,460
-96,400
-6% -$859K 0.04% 534
2014
Q1 		$12.8M Buy
1,540,860
+1,216,051
+374% +$10.4M 0.04% 511
2013
Q4 		$2.74M Sell
324,809
-352,861
-52% -$2.97M 0.01% 1173
2013
Q3 		$5.4M Sell
677,670
-2,298,008
-77% -$18.5M 0.02% 780
2013
Q2 		$23M Buy
+2,975,678
New +$23.2M 0.08% 310

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AQR Capital Management's PDLI Position: Q4 2020 in Review

AQR Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 262,907 shares — an estimated $828K sold.

AQR Capital Management first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $23M in Q2 2013. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • AQR Capital Management reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • AQR Capital Management sold 262,907 PDL BioPharma, Inc. shares in Q4 2020, an estimated $828K.
  • AQR Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • AQR Capital Management's PDL BioPharma, Inc. position peaked at $23M in Q2 2013.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on AQR Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.